Company Overview and News

 
Actinogen Medical presenting successes with Xanamem at BIO International

2018-05-31 proactiveinvestors.com.au
Actinogen Medical Ltd (ASX:ACW) CEO and managing director Dr. Bill Ketelbey speaks to Proactive Investors about progress with its promising cortisol inhibitor, Xanamem.
AEF ACW AHCLF

 
Actinogen Medical attracts $15 million to progress Alzheimer’s disease therapy

2018-05-23 proactiveinvestors.com.au
Actinogen Medical Ltd (ASX:ACW) has successfully raised $15 million through an institutional placement at a price of 5 cents per share.
AEF ACW AHCLF

12
Spin-off with benefits: Wesfarmers without Coles may attract ethical funds

2018-04-11 theage.com.au
Wesfarmers is set to become more attractive to ethical investors without the baggage of Coles and coal. It's a different story for the stand-alone supermarket chain.
MS AEF AHCLF

12
Spin-off with benefits: Wesfarmers without Coles may attract ethical funds

2018-04-11 smh.com.au
Wesfarmers is set to become more attractive to ethical investors without the baggage of Coles and coal. It's a different story for the stand-alone supermarket chain.
MS AEF AHCLF

5
Antisense Therapeutics raising $5+ million for muscle-wasting disease trials

2018-04-06 proactiveinvestors.com.au
Antisense Therapeutics Limited (ASX:ANP) has successfully completed a share placement to Australian Ethical Investment to raise $581,614 at 2.4 cents each.
ATHJY IONS ANP AEF ATHJF AHCLF

 
Immutep Ltd raises $6.8 million to fund immuno-oncology clinical development program

2018-03-11 proactiveinvestors.com.au
Immutep Ltd (ASX:IMM) has raised about $6.8 million through the placement of more than 326 million new fully paid ordinary shares at an issue price of 2.1 cents.
PTM AEF AHCLF

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

19h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

Silicon Investor Message Boards

This table lists all message boards related to ASX:AEF / AUSTRALIAN ETHICAL INVESTMENT LIMITED on message board site Silicon Investor.

Bernie Schaefferu0027s - Option program Bernie Schaefferu0027s - Option program Bernie Schaefferu0027s - Option program